Skip to main content
. 2022 Apr 12;13:772368. doi: 10.3389/fimmu.2022.772368

Figure 1.

Figure 1

Enrollment of DILI patients and healthy control subjects. CHB, chronic hepatitis B; AIH, autoimmune hepatitis; NAFLD, nonalcoholic fatty liver disease; HHT, hereditary hemorrhagic telangiectasia; MDA, malondialdehyde; GSH-Px, glutathione peroxidase; FGF19, fibroblast growth factor 19. (Created with BioRender.com.).